Resonance Health: Half Yearly Report and Accounts
Filed with ASX · · 27 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenues from ordinary activities, while the company also reported a notable loss after tax attributable to its owners. The document includes a review of operations, highlighting the company's core business in software-as-medical-device technologies and its involvement in clinical trials. No dividends were declared during this financial period, and the report includes an auditor's review of the financial statements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Resonance Health
- Non-deal Investor Roadshow Presentation
- Resonance Contracted by Major Global Pharma
- Trading Halt
- Full Year Results Presentation
- Full Year Results
Later from Resonance Health
- TrialsWest Expands with New Clinical Trial Site
- Appendix 4E & Full Year Statutory Accounts
- FY25 Full Year Results & FY26 Guidance Investor Presentation
- Investor Strategy Day Presentation
- AGM Presentation
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health